AI assistant
Alset Inc. — Director's Dealing 2025
Apr 4, 2025
34175_dirs_2025-04-04_893b57dd-97c6-4205-9181-101164b90174.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IMPACT BIOMEDICAL INC. (IBO)
CIK: 0001834105
Period of Report: 2025-04-02
Reporting Person: Chan Heng Fai Ambrose (Director, 10% Owner)
Reporting Person: Alset International Ltd (10% Owner)
Reporting Person: Alset Inc. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-02 | Common stock | S | 300000 | $0.581 | Disposed | 553904 | Indirect |
| 2025-04-02 | Common stock | S | 200000 | $0.674 | Disposed | 353904 | Indirect |
| 2025-04-02 | Common stock | S | 2349 | $0.673 | Disposed | 351555 | Indirect |
| 2025-04-02 | Common stock | S | 382427 | $0.583 | Disposed | 351631 | Indirect |
| 2025-04-03 | Common stock | S | 351631 | $0.579 | Disposed | 0 | Indirect |
| 2025-04-03 | Common stock | S | 273286 | $0.779 | Disposed | 180000 | Indirect |
| 2025-04-04 | Common stock | S | 180000 | $0.96 | Disposed | 0 | Indirect |
Footnotes
F1: On April 2, 2025, Alset International Limited sold 300,000 shares of the Issuer's common stock at a weighted average sale price of $0.581. This transaction was executed in multiple trades at prices ranging from $0.551 to $0.607. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2: On April 2, 2025, Alset International Limited sold 200,000 shares of the Issuer's common stock at a weighted average sale price of $0.674. This transaction was executed in multiple trades at prices ranging from $0.67 to $0.80. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: On April 2, 2025, Alset International Limited sold 2,349 shares of the Issuer's common stock at a weighted average sale price of $0.673. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F4: On April 2, 2025, Alset Inc. sold 382,427 shares of the Issuer's common stock at a weighted average sale price of $0.583. This transaction was executed in multiple trades at prices ranging from $0.57 to $0.63. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F5: On April 3, 2025, Alset Inc. sold 351,631 shares of the Issuer's common stock at a weighted average sale price of $0.579. This transaction was executed in multiple trades at prices ranging from $0.50 to $0.73. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F6: On April 3, 2025, Global Biomedical Pte. Ltd. sold 273,286 shares of the Issuer's common stock at a weighted average sale price of $0.779. This transaction was executed in multiple trades at prices ranging from $0.75 to $0.84. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F7: On April 4, 2025, Global Biomedical Pte. Ltd. sold 180,000 shares of the Issuer's common stock at a weighted average sale price of $0.96 This transaction was executed in multiple trades at prices ranging from $0.93 to $0.997. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F8: Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan now may be deemed to be the beneficial owner of the 351,555 shares of common stock held by Alset International Limited.